Legend Biotech develops cell therapies for cancer, with its flagship product cilta-cel (Carvykti) for relapsed or refractory multiple myeloma commercialized with Johnson & Johnson. The company focuses on CAR-T and related autologous cell platforms rather than traditional small-molecule drugs. Its pipeline and partnerships target hematologic malignancies and aim to expand cell therapy beyond the first commercial indication.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 255.1 | — | -125.4 | — |
| Q3 2025 | 272.3 | — | -39.7 | — |
| Q4 2025 | 306.4 | — | -30.8 | — |
| Q1 2026 | 305.1 | — | -54.3 | — |
| Q2 2026 | 387.5 | 51.9% | 33.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Wingstop Inc. (WING), Freshworks Inc. (FRSH), Universal Display Corporation (OLED), iRhythm Holdings, Inc. (IRTC), Fastly, Inc. (FSLY), WesBanco, Inc. (WSBC)